Compare QH & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QH | KALA |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 6.0M |
| IPO Year | 2020 | 2017 |
| Metric | QH | KALA |
|---|---|---|
| Price | $1.15 | $0.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 828.8K | ★ 22.0M |
| Earning Date | 09-26-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $357,118,848.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.74 | $0.51 |
| 52 Week High | $169.07 | $20.60 |
| Indicator | QH | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 37.46 |
| Support Level | $1.23 | $0.51 |
| Resistance Level | $2.20 | $0.67 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 11.24 | 10.20 |
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.